Agate Pass Investment Management LLC Has $4.47 Million Stake in Johnson & Johnson $JNJ

Agate Pass Investment Management LLC trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.0% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 29,247 shares of the company’s stock after selling 307 shares during the quarter. Johnson & Johnson accounts for 1.8% of Agate Pass Investment Management LLC’s investment portfolio, making the stock its 14th largest holding. Agate Pass Investment Management LLC’s holdings in Johnson & Johnson were worth $4,468,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. First Fiduciary Investment Counsel Inc. raised its position in shares of Johnson & Johnson by 1.1% during the second quarter. First Fiduciary Investment Counsel Inc. now owns 93,097 shares of the company’s stock worth $14,221,000 after purchasing an additional 998 shares during the period. Strengthening Families & Communities LLC grew its holdings in Johnson & Johnson by 10.7% during the second quarter. Strengthening Families & Communities LLC now owns 2,031 shares of the company’s stock worth $337,000 after buying an additional 196 shares in the last quarter. Blue Zone Wealth Advisors LLC grew its holdings in Johnson & Johnson by 4.8% during the second quarter. Blue Zone Wealth Advisors LLC now owns 1,768 shares of the company’s stock worth $270,000 after buying an additional 81 shares in the last quarter. JB Capital LLC grew its holdings in Johnson & Johnson by 4.2% during the second quarter. JB Capital LLC now owns 9,011 shares of the company’s stock worth $1,377,000 after buying an additional 360 shares in the last quarter. Finally, Blue Trust Inc. grew its holdings in Johnson & Johnson by 1.6% during the second quarter. Blue Trust Inc. now owns 66,941 shares of the company’s stock worth $10,225,000 after buying an additional 1,066 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

JNJ has been the subject of several recent research reports. Guggenheim upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and upped their price target for the stock from $167.00 to $206.00 in a report on Tuesday, September 23rd. Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. Piper Sandler reiterated an “overweight” rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Citigroup upped their price target on Johnson & Johnson from $200.00 to $213.00 and gave the stock a “buy” rating in a report on Tuesday, October 7th. Finally, Wells Fargo & Company set a $212.00 price target on Johnson & Johnson and gave the stock an “overweight” rating in a report on Friday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average price target of $192.94.

Johnson & Johnson Stock Down 0.2%

Shares of NYSE:JNJ opened at $190.66 on Monday. The company has a market capitalization of $459.16 billion, a PE ratio of 20.39, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The business has a fifty day moving average price of $178.48 and a two-hundred day moving average price of $163.78. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $192.10.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The firm had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. Analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a dividend of $1.30 per share. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. Johnson & Johnson’s dividend payout ratio is presently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.